Higher diagnostic accuracy reported for dementia experts vs primary care doctors before disclosure of test results, but not after.

Clinicians should maintain a high index of suspicion for Cyclospora in patients presenting with prolonged or relapsing watery diarrhea this summer.

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

The transition from accelerated to traditional approval is backed by robust 24-month eGFR data from the phase 3 APPLAUSE-IgAN trial.

At 12 months, adults with insulin-treated diabetes had significant improvements in HbA1c and hospitalizations.

Following a manufacturing-related Complete Response Letter in June 2026, the resubmitted application for the once-monthly subcutaneous depot is back under FDA review.

Supported by phase 3 SYMPHONY and ENCORE trial data, AXS-12 significantly reduced weekly cataplexy attacks and improved daytime sleepiness and cognition.

Targeting effective control of rheumatoid arthritis disease activity is crucial component of treatment strategy.

Treatments for fibrodysplasia ossificans progressiva, gastroenteropancreatic neuroendocrine tumors, HIV, influenza, and multiple myeloma are under review.

By neutralizing circulating dipeptidyl peptidase 3, the novel monoclonal antibody aims to reverse RAAS dysregulation and stabilize cardiovascular hemodynamics.

Most ION events occurred in men, patients 50 years or older, with minimal risk seen in women, patients younger than 50 years ...